Denali Advisors LLC Supernus Pharmaceuticals, Inc. Transaction History
Denali Advisors LLC
- $916 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding SUPN
# of Institutions
281Shares Held
60.6MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$370 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$218 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$181 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$103 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$93.7 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.9B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...